Fixed-dose ivermectin for Mass Drug Administration: Is it time to leave the dose pole behind? Insights from an Individual Participant Data Meta-Analysis
An age-based fixed-dose regimen for IVM could improve treatment coverage and simplify MDA activities. Simplified logistics could lead to cost savings in drug distribution and administration, improving the overall efficiency of MDA programs. These findings support the inclusion of currently excluded PSAC in IVM-based MDA interventions. More broadly, this paper provides evidence for considering the potential policy and programmatic implications of fixed-dose IVM. This Individual Participant Data Meta-analysis (IPD-MA) is registered in PROSPERO (CRD42024521610).
Authors
- Gabriela Matamoros (ORCID: https://orcid.org/0000-0003-2177-9765)
- Wendemagegn Enbiale (ORCID: https://orcid.org/0000-0002-0692-850X)
- Adriana Echazú (ORCID: https://orcid.org/0000-0002-3670-905X)
- Pedro Fleitas (ORCID: https://orcid.org/0000-0001-6574-4586)
- Julie Jacobson (ORCID: https://orcid.org/0000-0002-8243-6427)
- Alan D. Brooks (ORCID: https://orcid.org/0000-0002-4666-1934)
- Alejandro Krolewiecki (ORCID: https://orcid.org/0000-0001-9054-1211)
- Charles Mwandawiro (ORCID: https://orcid.org/0000-0001-8175-3749)
- Áuria de Jesus
- Daniela Bonanno
Institutions
- National University of Salta (AR)
- Kenya Medical Research Institute (KE)
- Manhiça Health Research Centre (MZ)
- National Autonomous University of Honduras (HN)
- Barcelona Institute for Global Health (ES)
- Bahir Dar University (ET)
Publication Details
- Journal
- PLoS neglected tropical diseases
- Published
- 2025-09-15
- DOI
- https://doi.org/10.1371/journal.pntd.0013059
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00